title: Insulin-mediated glucose disposal in type 1 (insulin-dependent) diabetic subjects treated by continuous subcutaneous or intraperitoneal insulin fusion.
abstract: In order to determine if intraperitoneal insulin infusion could improve the insulin resistance of type 1 diabetic patients we have used the englycaemic insulin clamp technique in order to study the effects of insulin on glucose disposal in four C peptide negative type 1 diabetic patients treated by continuous subcutaneous or intraperitoneal insulin infusion and in five control subjects. Compared to control subjects, the diabetic patients treated by subcutaneous insulin infusion had a decreased maximal capacity of glucose utilization (diabetics: 12.6 +/- 0.3 mg.kg-1.min-1; controls: 15.7 +/- 0.7 mg/kg-1.min-1, p less than 0.01) and a trend towards higher half-maximally effective insulin concentrations (diabetics: 70 +/- 11 mU/l-1, controls: 48 +/- 4 mU/l-1). Treatment of the diabetic patients by intraperitoneal insulin infusion for 2 months decreased their mean peripheral free insulin levels (during subcutaneous infusion: 23.5 +/- 2.2 mU/l-1; during intraperitoneal infusion: 18.4 +/- 1.4 mU/l-1, p less than 0.05). However, mean daily insulin requirements were not decreased (during subcutaneous infusion: 0.59 +/- 0.05 U/kg-1.day-1; during intraperitoneal infusion: 0.57 +/- 0.03 U/kg-1.min-1). Moreover, the diabetic patients had a consistently lower maximal capacity of glucose utilization (12.6 +/- 0.7 mg kg-1.min-1) than control subjects (p less than 0.01) without modification of the half-maximally effective insulin concentration (62 +/- 10 mU.l-1). In conclusion, the only benefit of intraperitoneal insulin infusion was a reduction of peripheral free insulin levels; this decrease of peripheral insulinaemia was not associated with an improvement in the insulin resistance of diabetic patients.
authors.affiliation: INSERM U. 197. Faculté de Médecine Alexis-Carrel, Lyon, France.
authors.forename: M
authors.initials: M
authors.lastname: Beylot
authors.forename: Y
authors.initials: Y
authors.lastname: Khalfallah
authors.forename: M
authors.initials: M
authors.lastname: Laville
authors.forename: G
authors.initials: G
authors.lastname: Sautot
authors.forename: H
authors.initials: H
authors.lastname: Dechaud
authors.forename: P
authors.initials: P
authors.lastname: Serusclat
authors.forename: F
authors.initials: F
authors.lastname: Berthezene
authors.forename: J P
authors.initials: JP
authors.lastname: Riou
authors.forename: R
authors.initials: R
authors.lastname: Mornex
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005943:Gluconeogenesis / Q000187:drug effects; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D007263:Infusions, Parenteral; D007328:Insulin / Q000097:blood; D007332:Insulin Infusion Systems; D007333:Insulin Resistance; D008297:Male
chemical_list: D001786:Blood Glucose; D007328:Insulin; D005947:Glucose